IN185276B - - Google Patents

Info

Publication number
IN185276B
IN185276B IN1579DE1996A IN185276B IN 185276 B IN185276 B IN 185276B IN 1579DE1996 A IN1579DE1996 A IN 1579DE1996A IN 185276 B IN185276 B IN 185276B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Min Lin
Dieter Schweiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN185276(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IN185276B publication Critical patent/IN185276B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
IN1579DE1996 1995-07-17 1996-07-16 IN185276B (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17

Publications (1)

Publication Number Publication Date
IN185276B true IN185276B (fi) 2000-12-16

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1579DE1996 IN185276B (fi) 1995-07-17 1996-07-16

Country Status (38)

Country Link
US (1) US6274740B1 (fi)
EP (1) EP0839132B1 (fi)
JP (1) JP4064459B2 (fi)
KR (1) KR100400805B1 (fi)
CN (1) CN1087289C (fi)
AR (1) AR002849A1 (fi)
AT (1) ATE199542T1 (fi)
AU (1) AU700794B2 (fi)
BG (1) BG63631B1 (fi)
BR (1) BR9609714A (fi)
CA (1) CA2220455C (fi)
CO (1) CO4700441A1 (fi)
CZ (1) CZ289421B6 (fi)
DE (1) DE69611999T2 (fi)
DK (1) DK0839132T5 (fi)
EA (1) EA000625B1 (fi)
EE (1) EE03605B1 (fi)
ES (1) ES2156997T3 (fi)
GE (1) GEP20002027B (fi)
GR (1) GR3035859T3 (fi)
HK (1) HK1018054A1 (fi)
HR (1) HRP960312B1 (fi)
HU (1) HU220343B (fi)
IL (1) IL122161A (fi)
IN (1) IN185276B (fi)
MX (1) MX9708959A (fi)
NO (1) NO309322B1 (fi)
NZ (1) NZ313008A (fi)
PE (1) PE1698A1 (fi)
PL (1) PL191017B1 (fi)
PT (1) PT839132E (fi)
RO (1) RO120069B1 (fi)
SI (1) SI0839132T1 (fi)
SK (1) SK283204B6 (fi)
UA (1) UA50743C2 (fi)
UY (1) UY24286A1 (fi)
WO (1) WO1997003960A1 (fi)
ZA (1) ZA966043B (fi)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (fi) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
MXPA03004276A (es) * 2000-11-16 2005-04-29 Teva Pharma Hidrolisis de esteres del acido (r(r*, r*)-2 -(4-fluorofenil)- beta, delta- dihidroxi-5 -(1-metiletil)- 3-fenil-4 -((fenilamino) carbonil)- 1h-pirrol-1 -heptanoico con hidroxido de calcio.
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (fi) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
WO2003004470A1 (en) 2001-06-29 2003-01-16 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
US7563911B2 (en) 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
AU2002356423A1 (en) * 2002-05-28 2003-12-12 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
ES2323366T3 (es) 2003-04-22 2009-07-14 Biocon Limited Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
CA2666359A1 (en) 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
EP1784389A4 (en) 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
TW200630335A (en) * 2004-10-18 2006-09-01 Teva Pharma Processes for preparing amorphous atorvastatin hemi-calcium
CN101048141A (zh) * 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2007103223A1 (en) * 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. Process for preparing a crystalline form of atorvastatin hemi-calcium
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
ES2167587T3 (es) 1995-07-17 2002-05-16 Warner Lambert Co Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina).

Also Published As

Publication number Publication date
DK0839132T5 (da) 2006-03-20
BR9609714A (pt) 1999-02-23
ZA966043B (en) 1997-02-03
SK5898A3 (en) 1998-08-05
NO980209D0 (no) 1998-01-16
IL122161A (en) 1999-07-14
UY24286A1 (es) 1997-01-17
HU220343B (hu) 2001-12-28
DE69611999T2 (de) 2001-07-26
BG63631B1 (bg) 2002-07-31
CN1087289C (zh) 2002-07-10
GR3035859T3 (en) 2001-08-31
HK1018054A1 (en) 1999-12-10
DK0839132T3 (da) 2001-04-09
IL122161A0 (en) 1998-04-05
PT839132E (pt) 2001-06-29
NO309322B1 (no) 2001-01-15
NZ313008A (en) 2000-01-28
BG102188A (en) 1998-08-31
UA50743C2 (uk) 2002-11-15
JPH11510486A (ja) 1999-09-14
RO120069B1 (ro) 2005-08-30
KR100400805B1 (ko) 2003-12-24
AU6497896A (en) 1997-02-18
SK283204B6 (sk) 2003-03-04
MX9708959A (es) 1998-03-31
CZ12298A3 (cs) 1998-12-16
US6274740B1 (en) 2001-08-14
HRP960312B1 (en) 2001-10-31
EE03605B1 (et) 2002-02-15
EA199800128A1 (ru) 1998-08-27
CN1190956A (zh) 1998-08-19
KR19990029045A (ko) 1999-04-15
WO1997003960A1 (en) 1997-02-06
EP0839132B1 (en) 2001-03-07
ATE199542T1 (de) 2001-03-15
JP4064459B2 (ja) 2008-03-19
ES2156997T3 (es) 2001-08-01
EE9700369A (et) 1998-06-15
EA000625B1 (ru) 1999-12-29
CA2220455A1 (en) 1997-02-06
AU700794B2 (en) 1999-01-14
EP0839132A1 (en) 1998-05-06
AR002849A1 (es) 1998-04-29
DE69611999D1 (de) 2001-04-12
GEP20002027B (en) 2000-04-10
SI0839132T1 (fi) 2001-06-30
PE1698A1 (es) 1998-02-19
CA2220455C (en) 2002-09-24
NO980209L (no) 1998-01-16
CO4700441A1 (es) 1998-12-29
PL191017B1 (pl) 2006-03-31
HRP960312A2 (en) 1998-02-28
PL324463A1 (en) 1998-05-25
CZ289421B6 (cs) 2002-01-16
HUP9903017A3 (en) 2001-01-29

Similar Documents

Publication Publication Date Title
DE69638352D1 (fi)
DE69637714D1 (fi)
BR122012014331A2 (fi)
BRPI9612258B1 (fi)
IN185276B (fi)
BRPI9612138B1 (fi)
DK143195A (fi)
CH0741373H1 (fi)
DK0727898T3 (fi)
BR7501503U (fi)
BR7502120U (fi)
IN187791B (fi)
DK126096A (fi)
AU1627395A (fi)
IN183651B (fi)
IN184540B (fi)
CN3030296S (fi)
CN3038187S (fi)
CN3031001S (fi)
CN3034591S (fi)
CN3031350S (fi)
CN3031655S (fi)
CN3030542S (fi)
CN3031742S (fi)
CN3030489S (fi)